US 11,867,706 B2
Methods and systems to measure cannabidiol (CBD)
Gregory C. Janis, Minneapolis, MN (US); and Melissa M. Goggin, North Branch, MN (US)
Assigned to Laboratory Corporation of America Holdings, Burlington, NC (US)
Filed by Laboratory Corporation of America Holdings, Burlington, NC (US)
Filed on Apr. 15, 2020, as Appl. No. 16/849,433.
Claims priority of provisional application 62/834,122, filed on Apr. 15, 2019.
Prior Publication US 2020/0326355 A1, Oct. 15, 2020
Int. Cl. G01N 33/94 (2006.01); G16B 50/30 (2019.01); G16B 50/20 (2019.01)
CPC G01N 33/948 (2013.01) [G16B 50/20 (2019.02); G16B 50/30 (2019.02); G01N 2560/00 (2013.01)] 16 Claims
 
1. A method of identifying a subject as a CBD user or a THC user by measuring relative levels of least one THC metabolite and at least one CBD metabolite in a urine sample obtained from a subject comprising the steps of:
(a) performing tandem MS/MS on the urine sample to obtain MS/MS data comprising a predetermined MS/MS transition for the at least one THC metabolite and the at least one CBD metabolite, wherein the predetermined MS/MS transition comprises a transition for at least one predefined precursor ion of defined m/z and at least one quantitative fragment ion of a defined m/z for each of the at least one THC metabolite and the at least one CBD metabolite, and wherein the at least one THC metabolite comprises 11-carboxy Δ9-THC (COO-THC) and THC released from Δ9-THC glucuronide, and the at least one CBD metabolite comprises 7-carboxy-CBD (COO-CBD) and CBD released from CBD glucuronide;
(b) determining an amount of the at least one THC metabolite and the at least one CBD metabolite in the urine sample based on the transitions in step (a); and
(c) determining a ratio of the amount of the at least one CBD metabolite to the amount of the at least one THC metabolite for the urine sample, wherein the ratio indicates CBD use or THC use in the subject from whom the urine sample is obtained, thereby identifying the subject as either a CBD user or a THC user.